Earnings call transcript: Oncolytics Biotech Q4 2024 shows strategic focus

Oncolytics Biotech Inc. (ONCY) reported its Q4 2024 financial results, presenting a net loss of $8 million, compared to $3.9 million in the same quarter of the previous year. According to InvestingPro data, the company is quickly burning through cash, though it maintains a healthy current ratio of 2.99x, indicating strong short-term liquidity. Despite the loss, the company’s stock decreased by 4.75% to $0.735, reflecting investor concerns. The earnings per share (EPS) was reported at -$0.1, better than the forecasted -$0.1171. The company maintains a strategic focus on its flagship product, Pelarirep, with ongoing trials in multiple cancer types.

Key Takeaways

• Oncolytics Biotech’s Q4 net loss increased to $8 million from $3.9 million a year earlier.
• EPS of -$0.1 exceeded the forecast of -$0.1171.
• The company is advancing trials for Pelarirep in breast, anal, and pancreatic cancers.
• Stock price fell by 4.75% following the earnings announcement.

Company Performance

Oncolytics Biotech’s performance in Q4 2024 was characterized by an increased net loss compared to the previous year, reflecting higher operational costs as the company invests in its clinical trials. The focus remains on developing Pelarirep, a promising therapeutic in oncology, with ongoing studies in breast, anal, and pancreatic cancers. The company is actively seeking a new CEO to drive future growth.

Financial Highlights

• Cash and cash equivalents: $15.9 million as of December 31, 2024
• Net cash used in operating activities: $27 million in 2024, down from $28.4 million in 2023
• Full-year net loss: $31.7 million, compared to $27.8 million in 2023
• Basic and diluted loss per share: $0.41

Earnings vs. Forecast

Oncolytics Biotech reported an EPS of -$0.1, surpassing the forecast of -$0.1171. This marks a slight improvement in performance, although the revenue remained at zero, consistent with expectations.

Market Reaction

The company’s stock declined by 4.75% to $0.735 following the earnings release. While this drop reflects investor concerns over the increased net loss and the absence of immediate revenue, InvestingPro data shows the stock has actually gained over 11% in the past week. The stock is currently trading below its InvestingPro Fair Value, suggesting potential upside opportunity. For deeper insights into ONCY’s valuation and 12+ additional ProTips, consider exploring the comprehensive Pro Research Report available on InvestingPro.

Executive Commentary

Wayne Passano, Interim CEO, highlighted the potential impact of Pelarirep, stating, "We estimate that as many as fifty-five thousand breast cancer patients would benefit from Pelo Rio Rep." Chief Medical Officer Tom Heinemann emphasized the strength of their clinical data, which "continue to exceed our expectations."

Risks and Challenges

• The ongoing search for a permanent CEO could impact strategic continuity.
• The company faces competition from other cancer therapies, including ADCs and CDK4/6 inhibitors.
• Financial sustainability remains a concern, with significant cash burn and no immediate revenue stream.
• Regulatory hurdles and clinical trial outcomes could affect future product launches.

Oncolytics Biotech continues to navigate the challenges of the biotech sector while focusing on strategic developments in its cancer therapeutics pipeline.

Full transcript - Oncolytics Biotech Inc (ONCY) Q4 2024:

Conference Operator: Good morning, and welcome to Oncolytics Biotech’s Fourth Quarter and Full Year twenty twenty four Conference Call. All participants are in a listen only mode.

There will be a question and answer session at the end of the call. Please be advised that this call is being recorded at the company’s request. I would now like to turn the call over to Jan Patton, Director of Investor Relations and Communications. Please go ahead.

Jan Patton, Director of Investor Relations and Communications, Oncolytics Biotech: Thank you, operator. Good morning, everyone, and welcome to Oncolytics’ fourth quarter and full year twenty twenty four earnings call. As a reminder, various remarks made during this call contain certain forward looking statements relating to the company’s business prospects and the development and commercialization of Pelarirep, including statements regarding the company’s mission, strategy and milestones, the company’s belief as to the potential and mechanism of action of Pelarirep as a cancer therapeutic, our search for a new permanent CEO, our potential registrational opportunities for Pelarirep and our plans and strategies related thereto, the potential market for Pelarirep and breast cancer, our plans to continue enrollment in Goblet Cohort five, our ongoing business development initiatives and other statements related to anticipated developments in the company’s business. These statements are based on management’s current expectations and beliefs and are subject to a number of factors which involve known and unknown risks, delays, uncertainties and other factors not under the company’s control may cause actual results, performance or achievements of the company to be materially different from the results, performance or expectations implied by these forward looking statements. In any forward looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have reasonable basis, but there can be no assurance that these statements, expectation or belief will be achieved.

These factors include results of current or pending clinical trials, risks associated with intellectual property protection, financial projections, actions by regulatory agencies and those other factors detailed in the company’s filings with SEDAR and the SEC. Our clients will not undertake any obligation to update these forward looking statements except as required by applicable laws. Joining me this morning to discuss our recent accomplishments in addition to what we’re looking forward to in 2025 are Chairman of Oncotic’s Board of Directors and Interim CEO, Wayne Passano Chief Medical Officer, Doctor. Tom Heinemann Chief Financial Officer, Kirk Look and Vice President of Business Development, Christophe DeGuail. To get us started, I’d like to hand it to Wayne, who will provide us with an introduction and overview.

Wayne?

Wayne Passano, Chairman of Board and Interim CEO, Oncolytics Biotech: Thanks, John. And thanks everyone for joining our twenty twenty four year end conference call. First, I’d like to reiterate my and the entire team’s best wishes for Doctor. Matt Coffey as he focuses full time on his recovery. Many of you know that Matt is a co founder of the company and he has a passion for improving the lives of cancer patients.

So this is not a decision that was taken lightly. Matt’s knowledge and expertise on Tolario Rep and immuno oncology is impressive. He will always be a strong advocate of Tolario Rep and we anticipate that he will support Oncolytics in an advisory role later this year. We are actively searching for a Chief Executive Officer to lead the company’s advancement of our novel therapeutic agent, Pella Rio Rep or Pella as we refer to it. We believe the opportunity for Pella is very compelling as we see the potential for an accelerated approval pathway in HR positive, HR2 negative metastatic breast cancer.

And our exciting work in gastrointestinal tumors continues to garner attention from collaborators like GCAR and PanCAN in addition to key opinion leaders in

: the field. I’ll leave it

Wayne Passano, Chairman of Board and Interim CEO, Oncolytics Biotech: to Tom to discuss our clinical data in more detail, but I’d like to highlight that in 2024, we generated outstanding final data in the BRACELET one breast cancer study that not only met, but exceeded our expectations. We also furthered our work in GI cancers with the ongoing goblet study. Initial safety and efficacy data in both pancreatic and anal cancers are positive. After Tom, Christoff will provide us with an overview of our business development progress and Kirk will discuss our financials. I’d like to remind everyone that on our last call, Christophe provided a detailed analysis of the breast cancer market.

Even with the introduction of the ADCs, breast cancer remains an unmet medical need for many patients. We estimate that as many as fifty five thousand breast cancer patients would benefit from Pelo Rio Rep. The efficacy data generated in both breast and gastrointestinal cancer trials demonstrate the potential of Pelo Rio Rep in hard to treat and very diverse tumor types. We remain focused on advancing the development of telareorep for cancer patients and value generation for our shareholders. I’ll now turn it over to Tom to discuss our clinical program updates.

Tom?

Tom Heinemann, Chief Medical Officer, Oncolytics Biotech: Thanks, Wayne. The recent impactful GI data that Wayne mentioned were presented in late January at the ASCO GI Conference. From goblet Cohort four, which investigates PELLA and the checkpoint inhibitor atezolizumab in relapsed anal cancer, we reported a thirty three percent objective response rate from the 12 evaluable patients, including a complete response that lasted more than fifteen months. In addition, we reported translational data from this cohort showing the expansion of new and pre existing tumor infiltrating lymphocyte clones in the blood of patients who responded to treatment with pellegririb combined with atezolizumab. We also saw the upregulation of multiple cytokines in these patients, including CXCL9, ten and eleven, as well as PD L1 and interferon gamma.

These results from patients with relapsed anal cancer support Pella’s immunologic mechanism of action as previously defined in other cancers. Specifically, they demonstrate Pella’s ability to enhance anti tumor T cell responses and its complementary effect of making tumors visible to the immune system. In addition, these findings provide evidence of Pella’s ability to synergize with checkpoint inhibitors in cancers that have historically resisted immune therapies. We have begun enrollment into Stage two of this SIMON2 stage study, which will provide data from an additional 18 patients. We believe the confirmation of the efficacy signal from these patients would provide a strong foundation for a subsequent registrational trial in anal cancer.

At ASCO GIA this past January, we also presented safety results from goblet cohort five. In this cohort, patients with metastatic pancreatic cancer are being treated with PELLA combined with modified filperinox either with or without atezolizumab in two treatment arms. No safety signals were observed during the safety run-in period and both an independent Data Safety Monitoring Board and the German regulatory authorities have approved the cohort to continue to full enrollment. We are now working towards achieving the next enrollment milestone, completion of enrollment into Stage one of the Simon two stage cohort, which consists of a total of 30 evaluable patients. We expect to review and report the initial efficacy results from this cohort by the end of the year.

Note that this cohort is funded by a $5,000,000 grant from the Pancreatic Cancer Action Network or PANCAM through their therapeutic accelerator award based on compelling prior pancreatic cancer results, including from cohort one of the goblet study in which patients treated with Pella combination therapy showed an objective response rate more than double historical results. While our GI cancer studies have provided results most recently, our top priority remains breast cancer, specifically metastatic HR positive HER2 negative breast cancer in which Pella has previously demonstrated a marked statistically significant near doubling of median overall survival in the IND-two 13 study. In light of this exciting result, we conducted the BRACE-one study to confirm the robust efficacy signal observed in IND-two 13 and to extend the evaluation of pelle to patients who had previously received CDK4six inhibitors, which are now part of the standard treatment regimen for patients with advanced or metastatic HR positive HER2 negative breast cancer. This past fall, the final efficacy results from the BRACEV-one study became available and they once again pointed to a clinically meaningful benefit for patients treated with PELLA based combination therapy to those treated with chemotherapy alone. In fact, all efficacy measures favored patients in the pellet combination therapy arm compared to those in the chemotherapy alone arm.

These included median progression free survival, median overall survival, two year survival rate and confirmed objective response rate. With these results, we have now observed a substantial efficacy signal from two randomized trials that enrolled over 100 patients. We currently are planning to move directly to a large Phase two study of approximately one hundred and eighty hour plus HER2 negative advanced or metastatic breast cancer patients that we anticipate will support an accelerated approval file submission. In this study, patients will be randomized to receive either Pella plus paclitaxel or control therapy of paclitaxel alone. The primary endpoint is expected to be reached within two years of the start of patient enrollment.

The planning for this study is ongoing and we aim to initiate the study in the second half of this year. In conclusion, the clinical data we have generated continue to exceed our expectations, provide extremely strong support for continued clinical development and provide clear path towards registration in breast, pancreatic and anal cancers, all difficult to treat cancers with high unmet needs. Now, I’ll turn the call over to Christophe, who will provide an update on our ongoing business development activities and collaborations. Christophe?

Christophe DeGuail, Vice President of Business Development, Oncolytics Biotech: Thanks, Tom. I’m happy to be here with you today to provide the latest update on our ongoing business development conversations. Since our last earnings call, we’ve continued to communicate to potential biopharma partners the substantial clinical benefit Pella has demonstrated across multiple heart treat indications. However, breast cancer is our highest priority. This is because we have data showing Pella’s benefit in two randomized breast cancer studies that exceed one hundred patients.

Also after discussion with regulators and key opinion leaders, we know where Pella should be positioned in the ever evolving breast cancer treatment paradigm. As for the clinical benefit and the final BRAHSA1 data reported this past fall, Pella combined with paclitaxel showed a greater than twelve months estimated advantage of paclitaxel monotherapy. However, as Tom mentioned, we also saw meaningful benefit in objective response rate, PFS and twenty four months overall survival. Our expected positioning of Pela in the treatment paradigm is for it to follow hormonal treatment like endocrine therapy, CDK4six inhibitors and targeted therapy and antibody drug conjugate like ERN2. However, some patients may not be eligible for or cannot tolerate ADCs.

So once a patient is eligible for chemotherapy, Pella would be a natural fit as our data with paclitaxel shows a robust benefit of paclitaxel monotherapy. As I discussed in great detail on our previous call, this is where we anticipate there will be fifty five thousand addressable breast cancer patients in The U. S. By 2027 and the potential for $2,400,000,000 in annual sales across The U. S.

And major European markets by 02/1933. Another important aspect of our BD conversation centers around where we will take PETA next on the regulatory pathway. After multiple discussions with key opinion leaders and statistician, we have designed a registration enabling breast cancer study that could generate a PFS endpoint within two years of the start of patient enrollment and be eligible for an accelerated approval file submission. We believe this is reasonable because a PFS benefit we would aim to achieve is four point three months, but the breastfed benefit was five point seven months. In our meetings, this is an aspect of our strategy that seems to be well understood and one that has already been used by other companies, including the approval of Ibrance for Pfizer and Enerto for Daiichi.

Now in future meetings, we will also layer in the most recent development that we presented at ASCO GI from our promising gastrointestinal opportunity. At this conversation progress, we’ll be sure to keep you updated. We’re in the fortunate position to have a compelling data in three indications: breast, pancreatic and anal cancers. These three indications demonstrate the broad potential for pelareoreb to help a large number of patients and provide a commercial opportunity that is appealing to potential biopharma partners. In the GI space, GCA and PanCan remain our valued collaborators.

We’re excited that Goblet Court five funded by PanCan is continuing to progress as planned and is now ready for full enrollment given the DSMB and TEI sign offs. As a reminder, PANCAM provided Oncolytics with a $5,000,000 grant to fully farm COR5 after an extensive vetting process and meeting with multiple pancreatic European leaders. As a highly regarded organization solely focused on pancreatic cancer, their vote of confidence in Pela’s potential give us confidence in the strategy to continue evaluation in this medication. Pancam continued interest in Pella is helping us to provide a more complete picture of Pella’s potential in this extremely difficult to treat type of cancer. This is due to the fact that the treatment regimen in this court is evaluating treatment with a different chemotherapy that we have used in the past, modified for Tranox.

This is one of the two most commonly administered to metastatic pancreatic cancer patients, the other being gemcitabine and napacitaxel. The combination of Pella plus gemcitabine, napacitaxel and atezolizumab showed a sixty two percent objective response rate, well above the usual twenty twenty five response rate that would be expected in a similar patient population. In turn, that data led to the relationship with PanCAN as well as a Fast Track designation from the FDA and the opportunity to collaborate with GCAR. We continue to engage with GCAR to finalize a master protocol for initiating a registration enabling study that could eventually lead to regulatory approval for the pelagemcitabine, napatlitaxel and atezolizumab combination. We look forward to sharing additional enrollment plan updates with you later this year.

Next, I’ll now turn the presentation over to Kirk for a review of our financials. Kirk?

Kirk Look, Chief Financial Officer, Oncolytics Biotech: Thanks, Christophe, and good morning, everyone. I’ll now discuss our financial results for the fourth quarter and full year 2024, which will be provided in Canadian dollars unless otherwise noted. A full summary of our financial results can be found on the Investors section of our website under Filings and Reports or in the press release issued earlier this morning. Now throughout 2024, we remained cautious with our cash resources. As of 12/31/2024, the company reported 15,900,000 in cash and cash equivalents.

Net cash used in operating activities for 2024 totaled $27,000,000 compared to $28,400,000 for 2023, reflecting non cash working capital changes, partially offset by higher net operating activities in 2024. Our general and administrative expenses for the fourth quarter of twenty twenty four were $3,900,000 compared with $4,200,000 for the fourth quarter of twenty twenty three. The decrease was mainly attributed to lower personnel related expenses incurred in 2024 along with lower cash annual short term incentive awards. The decrease is partially offset by higher share based compensation expense. Research and development expenses for the fourth quarter of twenty twenty four were $4,600,000 compared to $4,700,000 for the fourth quarter of twenty twenty three.

The decrease was due to lower personnel related expenses related to lower cash annual short term incentive awards, mainly offset by higher clinical trial expenses and share based payment compensation expense. Net loss for the fourth quarter of twenty twenty four was $8,000,000 compared to a net loss of $3,900,000 for the fourth quarter of twenty twenty three. The basic and diluted loss per share was $0.1 in the fourth quarter of twenty twenty four compared to a basic and diluted loss per share of $0.05 in the fourth quarter of twenty twenty three. For the full year 2024, net loss totaled $31,700,000 compared to $27,800,000 in 2023 or $0.41 per share on a basic and fully diluted basis. As we look forward to 2025, we are confident in the vast potential that Pella holds for improving patient outcomes.

We are making progress as shown by the recent data on pancreatic and anal cancers announced at ASCO GI and we are dedicated to advancing Pella as effectively and efficiently as possible. Now before we wrap up today’s call, I’d like to thank everyone who continues to support our efforts from patients, providers and caregivers to our dedicated employees and most importantly our steadfast shareholders. On behalf of the entire management team at Oncolytics, thank you again for taking the time to join us today. Now, I would like to open the call up for Q and A. Operator?

Conference Operator: Thank you. And your first question comes from the line of Michael Freeman with Raymond James. Please go ahead.

Michael Freeman, Analyst, Raymond James: Hey, good morning, Kirk, Wayne, Tom, Christophe, John. Congratulations on closing out a strong year 2024 and looking like an action packed 2025. So getting excited for this. I guess one question I have is, as you get closer to launching the registration enabling study in metastatic breast, I’m wondering how you’re thinking about the total cost of that trial? And I know you did provide some sort of detail around timing, but if you could provide as much color on launch timing and initial readout timing as you can, that’d be terrific.

Kirk Look, Chief Financial Officer, Oncolytics Biotech: Sure. I can take that. So currently we are working at getting a study registration, pardon me, enrollment ready. And so what that means is we more or less finalized the protocol, we’ll be approaching the regulator just as a normal course activity. In the meantime, we’re working with identified sites through feasibility and working with their process to get them on board.

And then once we have that sites identified and ready to be put on board, we’ll look to bring them online and then we’ll start to and then we’ll be in a position to enroll. We’re targeting to be in that position as things progress, it will probably be later half of the year now. Once enrollment starts, it’s expected to be an eighteen month enrollment period with a six month maturity data maturity to get to PFS readout. In the interim, we’re looking at putting in place a futility analysis and we have to finalize that assessment, But our expectations right now is a futility analysis will take about fourteen months from the first patient enrolled to get to that point and then we can have the futility readout.

Michael Freeman, Analyst, Raymond James: Okay, great. And then any sharper estimations on total costs?

Kirk Look, Chief Financial Officer, Oncolytics Biotech: We’re working through that. Michael, I think it’s premature to speak to that in any great detail. But as we understand our sites and enrollment, their enrollment rates, etcetera, we’ll be able to have more color on that.

Michael Freeman, Analyst, Raymond James: Got you. Okay. Thank you. One more question. I’ve been noticing more news from oncolytic virus developers in the landscape.

And I wonder if you’re seeing increasing evidence that there’s a bit of a oncotic virus renaissance going on. And are you seeing increased interest from pharma as a result? Like I point specifically to CG Oncology, they’re able to raise about $200,000,000 at the end of last year on good data. And that’s a live virus. Curious how you’re seeing things curious for your perspective on all this?

Kirk Look, Chief Financial Officer, Oncolytics Biotech: Christophe, do you want to speak to that as to what you’ve heard on your end and I can follow-up and if others want to jump in, they can.

Christophe DeGuail, Vice President of Business Development, Oncolytics Biotech: No, happy to answer that. Yes, you’re exactly right. I mean, you’re talking about CG oncology. We also I don’t know, you may have seen also Candol, who has done a raise at the end of last year. So we definitely see more activities in that field.

I think that’s very beneficial for us because let’s remember that we have significant advantage being injected instead of I mean, IV injection and not an intratumoral. And that’s the Intratrimol has been sometimes a little complicated for big pharma companies. I’m not really interested in that. So we as I mentioned during the call, I think we continue to have a conversation with potential partners and we’ve seen that the fact how we position Apella in breast cancer, the multiple signal breast cancer obviously having very strong data, but also the strong signal we’ve seen in other indication pancreatic and annual resonate very well with potential companies. Kirk, do you want to add anything to that?

Kirk Look, Chief Financial Officer, Oncolytics Biotech: Yes. And what we’re noticing on kind of discussions and presentations with investors is again more interest in the OB space that we’re seeing. We’re seeing more dedicated clinicians, science experts from those investors sitting down and talking to us and walking through our data and our plan. And there’s been some comments on from their standpoint, just seeing some white space opportunities to generate return for them. And so their focus is on that.

They see some of them are seeing this as a real opportunity. So that in combination with what’s going on in the industry, I think there’s some pretty, I think, big and important data readouts coming from our competitors that will be important to help those investors continue looking at the space. And we’ve seen a real shift in that. So we’re excited to hopefully be part of that.

Michael Freeman, Analyst, Raymond James: Excellent. Yes, good rising tide situation, I hope. And if I could just shoehorn one last one in, I wonder on the on the pancreatic front and your alignment with GCAR, I understand that you’re working together to get that master protocol together.

Jan Patton, Director of Investor Relations and Communications, Oncolytics Biotech: First, is this will this be

Michael Freeman, Analyst, Raymond James: the first trial launched on the GCAR platform? And I recognize that it takes some time for this organization to unload and get together a master protocol. But I wonder if there is any way that this trial can be can be accelerated to launch?

Kirk Look, Chief Financial Officer, Oncolytics Biotech: John, can you speak to that?

Tom Heinemann, Chief Medical Officer, Oncolytics Biotech: Yes, I can speak to that. But we have been working as Kirk mentioned very actively with GCAR to finalize a licensure enabling study protocol. The next step would be as would be typical in this sort of situation to be to go to the regulators and get the FDA’s thoughts and move on from there. And so it’s really maybe a little early for us to say anything very specific about the timing until we talk to the FDA. But I can say with regard to accelerating it that we are working very actively with GTAR and so we’re moving things forward with them at the greatest possible pace.

Michael Freeman, Analyst, Raymond James: Okay. All right. Thank you very much. I look forward to seeing all your activity this year. I’ll pass it on.

Conference Operator: Thank you. Your next question comes from the line of Patrick Trucchio with H. C. Wainwright. Please go ahead.

: Good morning everyone. Thank you for taking our questions. Luis here for and for Patrick. Congratulations on the latest presentations. We are curious to know what your thoughts are around the positioning, the commercial positioning of Pella given that ADCs seem to have shown and continue to show positive results in the same patient’s population.

So you are probably going to focus on the patients that did not respond or are not eligible as you said for this kind of therapy. Is there any other population that you could target that regarding the ADCs and do you think that there is a potential also for a combination not just as a sequential treatment approach, but a combination with Enertoin and other AUCs? Thank you.

Tom Heinemann, Chief Medical Officer, Oncolytics Biotech: Okay. So Tom here, I can start there and then if Christophe or others want to jump in, they can. But you’re right, we do want to target patients who are ineligible for or who cannot tolerate ADCs. But in actuality, the largest population we expect to target will be patients who receive ADC therapy and then progress on ADC therapy, okay, which is going to be a very large population. The ADCs have been extremely successful drugs and have benefited a lot of patients, but they are not cures, right.

And so once a patient takes an ADC after at the appropriate time in their treatment path, they will eventually progress on that therapy and will at that point need the best possible treatment options. And so we think that we would be may very well provide an alternative there that would be very attractive, right. And then I’m sorry, what was the second part of your question, please?

: We were wondering if there’s any potential for combination with Oh, yes. And the drug therapies.

Tom Heinemann, Chief Medical Officer, Oncolytics Biotech: Yes, sorry. So, PELARIR rep in general has proven itself to be an agent that can potentiate the activity of other therapies, including chemotherapy and immunotherapies. So I think it’s a very logical thing to consider in the future. It’s not our immediate path for a variety of reasons now, but I think at the appropriate time in the future, combination therapy with ADCs and other agents would certainly be something worth considering.

Michael Freeman, Analyst, Raymond James: Great. Thank you.

Christophe DeGuail, Vice President of Business Development, Oncolytics Biotech: And yes, this is Christophe. I can add a little color on the more on the number of patients for you. As you may recall, we discussed a total addressable patient population of 55,000 patients just in The U. S. And when you look at that, it’s mostly for patient who would have been on ERN02 and would have initially responded and then would relapse, which is as you look at RNO2, I mean your average PFS is ten to eleven months.

So we know that this patient at some point in time, we need another better treatment and another treatment. So when we build our forecast of that total to more than 2,000,000,000, that considers fifty five thousand patients annually in The U. S. And then we take a very conservative approach with 15% to 20% market share in this population. So that’s where we believe there’s a significant market opportunity.

Conference Operator: Any follow-up question?

: Thank you. That was very helpful. Great.

Conference Operator: Thank you. And I’m showing no further questions at this time. I would like to turn it back to Kirk Look for closing remarks.

Kirk Look, Chief Financial Officer, Oncolytics Biotech: Well, thanks to everybody who took the time to join our earnings call this morning. This is going to be an exciting year for Pella and on clinics with additional data readouts expected in the planning of registration enabling studies that can move Pella closer to regulatory approval. Thanks again for your support and we will have more updates as soon as we can. Wishing everyone a wonderful day. Thanks very much.

Conference Operator: Thank you, presenters. And ladies and gentlemen, this concludes today’s conference call. Thank you all for participating. You may now disconnect.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.